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Abstract 
DNA from 30 unrelated Spanish patients with familial hypercholesterolemia (FH) was studied by single-strand conformation 
polymorphisms (SSCP)/heteroduplex analysis for mutation detection i  exon 13 of low density lipoprotein (LDL) receptor gene. Two 
patients were found to have an abnormal pattern by heteroduplex analysis, and direct sequencing revealed a C to G substitution at 
nucleotide position 1965, that results in a Phe to Leu change in codon 634, F634L. We have developed a PCR based assay to detect his 
mutation in family members. We found three additional F634L mutation carriers, and all of them had high cholesterol levels. Haplotype 
analysis revealed that all F634L mutation carriers had the same allele determined by TaqI - ,  StuI +, Avail +, NcoI - ,  suggesting the 
presence of a common ancestor. We report a novel mutation located in exon 13 of the LDL receptor gene that causes FH. We also 
demonstrate the importance of combining SSCP and heteroduplex analysis to improve mutation detection. 
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Familial hypercholesterolemia (FH) is inherited in an 
autosomal dominant manner and is one of the most com- 
mon genetic diseases. It is caused by heterogeneous muta- 
tions in the low density lipoprotein (LDL) receptor gene 
[1]. The majority of mutations causing FH are point muta- 
tions or small deletions/duplications located along the 45 
kilobases (kb) of the LDL receptor gene [2]. Analysis of 
single-strand conformation polymorphisms (SSCP) has 
proved to be a powerful tool to detect point mutations in 
the LDL receptor gene [3,4]. 
As part of a project aimed at characterizing mutations in 
the LDL receptor gene underlying FH in Spain, we have 
applied single-strand conformation polymorphisms (SSCP) 
and heteroduplex analysis [5] to screen 30 unrelated Span- 
ish FH patients for point mutations in exon 13 of the LDL 
receptor gene. We report here a novel mutation in exon 13 
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causing FH. This point mutation results in substitution of 
phenylalanine for leucine at amino acid 634 of the LDL 
receptor. 
Using a previously described method [6], we isolated 
genomic DNA from peripheral blood from the FH patients 
sample. A fragment of the LDL receptor gene comprising 
exon 13 and its flanking regions (329 bp) was amplified 
using the polymerase chain reaction (PCR). We used the 
oligonucleotides 5'-GTCATCTTCCTTGCTGCCTG-3' and 
5'-TTCCAC-AAGGAGGTTTCAAGGTTGGGGGGG-3', 
and we subjected the genomic DNA to 35 cycles of 
denaturation at 94°C for 1 min, annealing at 59°C for 1 
min, and extension at 74°C for 3 min, followed by a final 
extension of 10 rain at 74°C. For SSCP and heteroduplex 
analysis, PCR products were radiolabelled with 32 P-dCTP, 
added to a formamide loading buffer, denatured at 94°C 
for 4 min, and electrophoresed at 6 W for 16 h, at room 
temperature, on a HydroLink-MDE gel (AT Biochem, 
Malvem, PA) with or without 5% glycerol, in a 0.6 × TBE 
buffer. The electrophoresis was stopped before the double 
strand DNA fragments reached the bottom of the gel, in 
order to be able to detect heteroduplex formation. The gels 
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were dried and autoradiographed for 3 -4  days. Direct 
sequencing was performed in an ABI DNA Sequencer 
(Model 373A) with a dye terminator kit, as previously 
described [7]. Nucleotide positions were numbered as sug- 
gested by Yamamoto et al. [8]. 
To detect the presence of the C to G substitution in 
position 1965, a PCR based assay was carried out amplify- 
ing a 255 bp fragment with primers 5 ' -AGTGCCAAC- 
CGCCTCACAGG-3'  and 5 ' -CCTCTCACACCAGTTCA- 
CTC-3', and denaturing for 1 min at 96°C, annealing for 2 
min at 62°C, and extending for l min 30 s at 74°C. This 
heating cycle was repeated 30 times followed by a final 
extension of 10 min at 74°C. An aliquot of 15 /xl of this 
PCR product was digested with 10 U of Mbol I  at 37°C for 
3 h. Following electrophoresis on 8% polyacrylamide gel, 
the digestion products were visualized with ethidium bro- 
mide. The haplotypes of FH family members were deter- 
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Fig. 2. Analysis of F634L mutation by PCR. Ethidium bromide stained 
8% polyacrylamide g l after electrophoresis of MbolI digested PCR 
products. F634L mutation destroys a MbolI cleavage site that is present 
in the normal allele. After cleavage with Mboll, either a 105, 66, 44 and 
40 bp fragments (wild type) or 171, 105, 66, 44 and 40 bp fragments 
(heterozygous mutant type) are produced. Lanes 1, 4, 6, 7, 10: Heterozy- 
gous F634L carriers; lanes 2, 3, 5, 8, 9: Normal relatives. 
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Fig. 1. SSCP/heteroduplex and sequence analysis of exon 13 of the LDL 
receptor gene. A. SSCP/heteroduplex patterns were observed without 
glycerol in the gel. Lanes 1 and 4: Control individuals homozygous for 
AvalI polymorphism, harboring a T or a C in position 1959, respectively. 
Lane 2: Control individual heterozygous for AvalI polymorphism, har- 
boring T/C in position 1959. Lane 3: FH heterozygous person harboring 
T/C in position 1959 and C/G in position 1965. Arrow indicates an 
extra band in heteroduplex analysis. B. Sequence of nucleotides 1954- 
1971 corresponding to lane 3 subject in panel A. Asterisk indicates AvaII 
polymorphism. Arrow indicates F634L mutation. 
mined using 4 polymorphisms in the LDL receptor gene. 
The variable restriction enzyme sites used were: TaqI in 
intron 4 [9], StuI in exon 8 [10], Avai l  in exon 13 [11] and 
NcoI in exon 18 [12]. These polymorphisms were detected 
by PCR amplification and restriction enzyme digestion. 
Alleles were designated as '+ '  to indicate presence or 
' - '  to indicate absence of the restriction site. 
SSCP-heteroduplex analysis and sequencing results are 
shown in Fig. 1. In the upper part of the gel (Fig. 1A), 
corresponding to SSCP analysis, no abnormal pattern due 
to a mutation can be distinguished. However, in the lower 
part or the gel, corresponding to heteroduplex formation, 
an extra band due to a nucleotide change is detected in two 
patients, PB I. 1 and RM 1.2. Direct sequencing of the exon 
13 of the LDL receptor gene revealed a C to G transver- 
sion in position 1965 that changes codon 634 from phenyl- 
alanine to leucine, F634L (Fig. 1B). A PCR based assay to 
detect the mutation F634L is shown in Fig. 2. The wild 
type exhibited 105, 66, 44 and 40 bp fragments after the 
255 bp PCR product was digested with Mbol t  restriction 
enzyme. The F634L mutation destroys a Mbol I  restriction 
site, and 171, 44 and 40 bp fragments are produced in the 
mutant allele. We studied all available family members of 
the two unrelated probands carrying the mutation. In both 
families PB and RM, 2 and 1 additional heterozygous FH 
patients with the F634L mutation, respectively, were iden- 
tified. Pedigrees of these two families are shown in Fig. 3. 
The lipid levels of family members tudied are shown 
in Table 1. Compared with the general Spanish population 
[13,14], all the F634L carriers had total and LDL choles- 
terol levels above the 95th percentile. In both FH families, 
lipid levels were higher in mutation carriers than in rela- 
tives without the F634L mutation. There were no signifi- 
cant differences in HDL cholesterol and triglycerides be- 
tween mutation carriers and non-mutation carriers. 
The LDL receptor genotypes of the family members 
were determined at four polymorphic sites within the LDL 
A. Cenarro et al. / Biochimica et Biophysica Acta 1316 (1996) J -4 3 
A.  Family PB 
1 2 
i  1--O 
II 
I "  
B.  Family RM 
1 2 
Fig. 3. Pedigrees of families PB and RM with the F634L mutation. The 
half-filled symbols represent the F634L mutation carriers. Arrow indi- 
cates probands. 
receptor gene. The haplotypes were deduced from the 
genotypes of relatives assuming there were no recombina- 
tion events within the family. The haplotype of the allele 
carrying the F634L mutation was TaqI - ,  StuI + ,  AraII 
+,  NcoI - .  
There are more than 150 different mutations in the LDL 
receptor gene causing FH. Many of these mutations disrupt 
receptor function in different ways that reveal much about 
the relationship between receptor structure and function 
[2]. In this work, we describe a novel mutation located in 
exon 13 of the LDL receptor gene. Exon 13 codes for a 
portion of the human epidermal growth factor (EGF) pre- 
cursor homology domain. This domain includes three 
growth factor repeats, which are 40 amino acid cysteine- 
rich sequences. The first two growth factor repeats (A and 
B) are separated from the third growth factor repeat (C) by 
a 280 amino acid sequence that contains five copies of a 
conserved motif, Tyr-Trp-Thr-Asp, repeated once each 40 
to 60 amino acids [1]. The EGF precursor homology 
domain is required for the acid-dependent dissociation of 
lipoproteins from the receptor in the endosome during 
receptor ecycling. It also serves to position the ligand 
binding domain so that it can bind LDL on the cell surface 
[15]. This domain is very highly conserved, and it has a 
compact structure that is easily disrupted even if only one 
single amino acid is changed [16]. Exon 13 codes for 47 
amino acid sequence at the end of the spacer egion, before 
the third growth factor repeat (C). The missense mutation 
F634L identified in codon 634 probably disrupts the pro- 
tein folding in a such way that transport of LDL receptor 
from endoplasmic reticulum to Golgi complex is blocked, 
like other mutations described in the EGF domain [2], and 
it is expected to cause class 2 alleles. 
The F634L mutation segregates with high lipid levels in 
the two families studied, and all the mutation carriers had 
lipid levels above the 95th percentile compared with the 
general Spanish population [13,14]. Furthermore, one of 
the probands carrying the mutation, RM 1.2, had the 
highest otal and LDL cholesterol levels in the sample of 
30 heterozygous FH subjects studied (14.8 and 13.1 
mmol/1, respectively). Therefore, the F634L mutation 
seems to be pathogenic and the cause of FH, as no other 
mutation in the rest of the gene could be detected in these 
two subjects by SSCP/heteroduplex and Southern blot 
analyses (data not shown). The Phe to Leu change does not 
involve any amino acid of the conserved motif Tyr-Trp- 
Thr-Asp, but the Phe in position 634 could be important 
for the correct folding of the protein. 
Only one mutation in exon 13 of the LDL receptor gene 
has been reported previously in a Chinese patient using 
SSCP [17]. We could not detect the F634L mutation by 
SSCP analysis only. However, using SSCP together with 
heteroduplex analysis as described above, we were able to 
detect an extra band corresponding to a nucleotide substi- 
tution. It is possible that the F634L mutation is refractory 
to detection by SSCP analysis due to the fact that it is only 
6 nucleotides downstream of the Acall polymorphism 
[11], and both unrelated subjects carrying this mutation 
were heterozygous for this polymorphic site. In contrast, 
the A606T mutation identified in the Chinese subject is 80 
nucleotides upstream of the A~,aIl polymorphism [17]. The 
genotype of this patient at that polymorphic site is not 
available, and thus, if the subject was homozygous for the 
At:aII site, the mutation would be easily detected by SSCP. 
It seems possible that other mutations in exon 13 lying in 
proximity to the AcalI polymorphism in heterozygous 
subjects could also be refractory to detection by SSCP 
analysis. 
Table 1 
Lipid values for the two families carrying the F634L mutation 
Subject Sex Age TC LDL-C HDL-C TG 
Family PB 
I. 1 * m 47  10.2  8.6 1.2 0.8 
1.2 f 45 5.6 3.8 1.4 0.7 
II.l * f 21 8.9 7.1 1.4 0.8 
II.2 f 20 4.8 2.8 1.7 0.7 
II.3 " f 15 7. I 5.3 1.5 0.6 
II.4 f 13 4.7 2.9 1.5 0.6 
Family RM 
1.1 m 61 5.6 3.6 0.9 2.2 
1.2 * f 65 14.8 13.1 1.0 1.4 
II. 1 m 33 5.4 3.4 1.4 1.2 
II.2 * f 27 8.8 6.5 1.7 1.1 
TC, total cholesterol; LDL-C. LDL cholesterol; HDL-C, HDL choles- 
terol; TG, triglycerides, all measured in mmol/I. Asterisk indicates 
subjects carrying F634L mutation. 
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In conclusion, a novel pathogenic mutation in exon 13 
of the LDL receptor gene is described. Further charac- 
terization of this F634L mutation will help us to under- 
stand better the functional properties of this portion of the 
EGF precursor homology domain. 
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